Clinical Trial Update: Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating two combination regimens for BRAFV600-mutant metastatic or unresectable melanoma: nivolumab with dabrafenib/trametini…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Melanoma

Drugs mentioned

• Binimetinib (binimetinib)
• Dabrafenib (Dabrafenib)
• Encorafenib (encorafenib)
• Trametinib (trametinib)
• nivolumab (nivolumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING